Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$72.80M

Industries

Biotechnology,Health Care,Pharmaceutical

Founded date

Jan 1, 2001

Number Of Employee

11 - 50

Operating Status

Active

Stock Symbol

szse:300142

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Walvax Biotechnology has acquired 1 organizations. Their most recent acquisition was Hebei Daan Pharmaceutical Co., Ltd on Oct 26, 2012. They acquired Hebei Daan Pharmaceutical Co., Ltd for ¥529M.

Date Company Name	Industry	Acquisition Type	Price
Oct 26, 2012 Hebei Daan Pharmaceutical Co., Ltd	Health Care	—	¥ 529M	Detail